Stay Connected. Manage Your Care.
Access your health information anytime and anywhere, at home or on the go, with MyHealth.
- Message your clinic
- View your lab results
- Schedule your next appointment
- Pay your bill
The MyHealth mobile app from Stanford Health Care puts all your health information at your fingertips and makes managing your health care simple and quick.
Guest Services
24/7
We are available to assist you
whenever you need it. Give us a call at
650-498-3333 or
PHYSICIAN HELPLINE
Have a question? We're here to help! Call 1-866-742-4811
Monday - Friday, 8 a.m. - 5 p.m.
REFER A PATIENT
Fax 650-320-9443
Track your patients' progress and communicate with Stanford providers conveniently and securely.
Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas
This is a single institution phase I / II trial to evaluate the safety, feasibility and
efficacy of CpG injections (4 intratumoral injections followed by 6 peri-tumoral injections)
combined with local irradiation in patients with recurrent low-grade lymphomas.
Patients will receive low-dose radiotherapy to a single tumor site on days 1 and 2 (2 Gy
each day). CpG injections will be administered into the same tumor site within the 24 hours
before and the 24 hours after the radiation, and on days 8 and 15. Weekly doses of CpG will
be then administered subcutaneously in the region of previous injections for 6 additional
doses.
Principal Investigator
Stanford Investigator(s)
- Sandra Horning
- Irene Wapnir
- Richard Hoppe
- Youn H Kim
- Susan Knox